76 results on '"Ray-Coquard, Isabelle"'
Search Results
2. Avancées thérapeutiques dans la prise en charge des tumeurs rares malignes ovariennes
- Author
-
Lebreton, Coriolan, Quesada, Stanislas, Bini, Marta, Babin, Guillaume, Rossi, Léa, Chopin, Nicolas, Croce, Sabrina, Hartog, Cécile, Renaud, Tiphaine, Gaillard, Anne-Lise, Petit, Adeline, Serre, Anne-Agathe, Trédan, Olivier, Rowinski, Elise, Cockenpot, Vincent, Treilleux, Isabelle, Rousset-Jablonski, Christine, Méeus, Pierre, Guyon, Frédéric, and Ray-Coquard, Isabelle
- Published
- 2023
- Full Text
- View/download PDF
3. Adénosarcomes mullériens de l’utérus – référentiels de prise en charge du GSF-GETO/NETSARC+ et du groupe TMRG
- Author
-
Karabajakian, Andy, Genestie, Catherine, Meeus, Pierre, Guyon, Frédéric, Llacer Moscardo, Carmen, Croce, Sabrina, Taieb, Sophie, Duffaud, Florence, Pautier, Patricia, Ray-Coquard, Isabelle, and Blay, Jean-Yves
- Published
- 2023
- Full Text
- View/download PDF
4. Sarcomes utérins du stroma de haut grade et sarcomes indifférenciés – Référentiels de prise en charge du Groupe Sarcome Français et du Groupe des Tumeurs Rares Gynécologiques
- Author
-
Roussel-Simonin, Cyril, Croce, Sabrina, Guyon, Frédéric, Llacer, Carmen, Ray-Coquard, Isabelle, Meeus, Pierre, Genestie, Catherine, Taieb, Sophie, Malhaire, Caroline, Duffaud, Florence, and Pautier, Patricia
- Published
- 2023
- Full Text
- View/download PDF
5. Diagnostic des sarcomes utérins et tumeurs mésenchymateuses utérines rares à potentiel de malignité. Référentiels du Groupe Sarcome Français et des Tumeurs Rares Gynécologiques
- Author
-
Croce, Sabrina, Devouassoux-Shisheboran, Mojgan, Pautier, Patricia, Ray-Coquard, Isabelle, Treilleux, Isabelle, Neuville, Agnès, Arnould, Laurent, Just, Pierre-Alexandre, Le frere Belda, Marie Aude, Averous, Gerlinde, Leroux, Agnès, Bataillon, Guillaume, Mery, Eliane, Loussouarn, Delphine, Weinbreck, Nicolas, Le Guellec, Sophie, Mishellany, Florence, Morice, Philippe, Guyon, Frédéric, and Genestie, Catherine
- Published
- 2023
- Full Text
- View/download PDF
6. Mise à jour 2021 des recommandations pour la pratique clinique de Nice/Saint-Paul-de-Vence dans le cancer de l’ovaire épithélial de haut grade: Updated 2021 recommendations for the clinical practice of Nice/Saint-Paul-de-Vence in epithelial high grade ovarian cancer
- Author
-
Joly, Florence and Ray-Coquard, Isabelle
- Published
- 2021
- Full Text
- View/download PDF
7. Les avancées actuelles de l’immunothérapie dans le cancer de l’ovaire
- Author
-
Le Saux, Olivia, Dubois, Bertrand, Stern, Marc-Henri, Terme, Magali, Tartour, Eric, Classe, Jean-Marc, Chopin, Nicolas, Trédan, Olivier, Caux, Christophe, and Ray-Coquard, Isabelle
- Published
- 2020
- Full Text
- View/download PDF
8. Prise en charge des carcinomes ovariens de haut grade séreux et/ou endométrioïdes de stades avancés (III-IV) et testing HRD-BRCA en 2023 : actualisation selon les données publiées et/ou présentées en 2022
- Author
-
Selle, Frédéric, Joly, Florence, Gladieff, Laurence, Prulhière, Karine, Leary, Alexandra, Kalbacher, Elsa, Rouleau, Etienne, and Ray-Coquard, Isabelle
- Published
- 2023
- Full Text
- View/download PDF
9. Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
- Author
-
Alexandre, Jérôme, Le Frère-Belda, Marie-Aude, Angelergues, Antoine, Ferron, Gwenaël, Treilleux, Isabelle, Gaillard, Anne-Lise, Frenel, Jean-Sébastien, You, Benoît, Rouleau, Etienne, Lortholary, Alain, Ray-Coquard, Isabelle, and Joly, Florence
- Published
- 2023
- Full Text
- View/download PDF
10. Texte court rédigé à partir de la recommandation nationale de bonnes pratiques cliniques « Conduites à tenir initiales devant des patientes atteintes d’un cancer épithélial de l’ovaire » élaborée par FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY et labélisée par l’INCa »
- Author
-
Lavoue, Vincent, Huchon, Cyrille, Akladios, Cherif, Alfonsi, Pascal, Bakrin, Naoual, Ballester, Marcos, Bendifallah, Sofiane, Bolze, Pierre-Adrien, Bonnet, Fabrice, Bourgin, Charlotte, Chabbert-Buffet, Nathalie, Collinet, Pierre, Courbiere, Blandine, De la Motte Rouge, Thibault, Devouassoux-Shisheboran, Mojgan, Falandry, Claire, Ferron, Gwenal, Fournier, Laure, Gladieff, Laurence, Golfier, François, Gouy, Sébastien, Guyon, Frédérique, Lambaudie, Eric, Leary, Alexandra, Lecuru, Fabrice, Lefrere-Belda, Marie-Aude, Leblanc, Eric, Lemoine, Adrien, Narducci, Fabrice, Ouldamer, Lobna, Pautier, Patricia, Planchamp, François, Pouget, Nicolas, Ray-Coquard, Isabelle, Rousset-Jablonski, Christine, Senechal-Davin, Claire, Touboul, Cyril, Thomassin-Naggara, Isabelle, Uzan, Catherine, You, Benoit, and Daraï, Emile
- Published
- 2019
- Full Text
- View/download PDF
11. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]
- Author
-
Rousset-Jablonski, Christine, Selle, Frédéric, Adda-Herzog, Elodie, Planchamp, François, Selleret, Lise, Pomel, Christophe, Chabbert-Buffet, Nathalie, Darai, Emile, Pautier, Patricia, Trémollières, Florence, Guyon, Frédéric, Rouzier, Roman, Laurence, Valérie, Chopin, Nicolas, Faure-Conter, Cécile, Bentivegna, Enrica, Vacher-Lavenu, Marie-Cécile, Lhomme, Catherine, Floquet, Anne, Treilleux, Isabelle, Lecuru, Fabrice, Gouy, Sébastien, Kalbacher, Elsa, Genestie, Catherine, de La Motte Rouge, Thibault, Ferron, Gwenaël, Devouassoux-Shisheboran, Mojgan, Kurtz, Jean-Emmanuel, Namer, Moïse, Joly, Florence, Pujade-Lauraine, Eric, Grynberg, Michael, Querleu, Denis, Morice, Philippe, Gompel, Anne, Ray-Coquard, Isabelle, Centre Léon Bérard [Lyon], CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Molécules Thérapeutiques in silico (MTI), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), École Nationale de la Statistique et de l'Administration Économique (ENSAE Paris), Institut Gustave Roussy (IGR), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Beninois pour l'Environnement et le développement économique et Social (CEBEDES), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Pitié-Salpêtrière [AP-HP], Chemistry, Oncogenesis, Stress and Signaling (COSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claudius Regaud, Service d'Anatomo-Pathologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Les Hôpitaux Universitaires de Strasbourg (HUS), Cancérologie (Inserm U599/IPC), Université de la Méditerranée - Aix-Marseille 2-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Oncologie médicale [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service d'Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Hôpital Hôtel-Dieu [Paris], Unité de Biologie Fonctionnelle et Adaptative (BFA (UMR_8251 / U1133)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de chirurgie générale [Gustave Roussy], Unité de Gynécologie, Health Service and Performance Research (HESPER), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Alliance Pour la Recherche En Cancérologie [CHU Tenon] (APREC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Gynécologie-obstétrique et médecine de la reproduction - Maternité [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie pathologique [CHU Pitié-Salpêtrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Institut National de la Santé et de la Recherche Médicale (INSERM)-CRLCC Eugène Marquis (CRLCC)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Tumeurs germinales ,Fertilité ,Delphi Technique ,Borderline ovarian tumor ,Menopause, Premature ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Carcinoma, Ovarian Epithelial ,Rare Diseases ,Sex cord tumor ,Germ cell tumor ,Humans ,Neoplasms, Glandular and Epithelial ,Rare ovarian tumor ,Hormone therapy ,Ovarian Neoplasms ,Contraindications, Drug ,Fertility Preservation ,Tumeur borderline ,Neoplasms, Germ Cell and Embryonal ,Traitement hormonal ,Contraception ,Fertility ,Female ,Tumeurs des cordons sexuels ,Tumeur rare de l’ovaire ,Infertility, Female - Abstract
National audience; Introduction - Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. Methods - A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. Results - Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. Discussion - In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.
- Published
- 2018
12. Le territoire, générateur d’inégalités face aux cancers
- Author
-
Fayet, Yohan, Chasles, Virginie, Ray-Coquard, Isabelle, Environnement, Ville, Société (EVS), École normale supérieure de Lyon (ENS de Lyon)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Jean Monnet - Saint-Étienne (UJM)-École Nationale des Travaux Publics de l'État (ENTPE)-École nationale supérieure d'architecture de Lyon (ENSAL)-Centre National de la Recherche Scientifique (CNRS), Service d'Oncologie Médicale, Centre Léon Bérard [Lyon], Environnement Ville Société (EVS), Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-École nationale supérieure d'architecture de Lyon (ENSAL)-École des Mines de Saint-Étienne (Mines Saint-Étienne MSE), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-École Nationale des Travaux Publics de l'État (ENTPE)-Université Jean Monnet [Saint-Étienne] (UJM)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), and Chasles, Virginie
- Subjects
[SHS.GEO] Humanities and Social Sciences/Geography ,[SHS] Humanities and Social Sciences ,[SHS.GEO]Humanities and Social Sciences/Geography ,ComputingMilieux_MISCELLANEOUS ,[SHS]Humanities and Social Sciences - Abstract
International audience
- Published
- 2017
13. Le territoire, générateur d’inégalités face aux cancers. Analyse de la cohorte EMS en Région Rhône-Alpes
- Author
-
Fayet, Yohan, Chasles, Virginie, Ducimetière, Françoise, Ray-Coquard, Isabelle, Chasles, Virginie, Santé Individu Société - SIS (SIS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université Lumière - Lyon 2 (UL2), Département d'Oncologie Médicale, Centre Léon Bérard [Lyon], Service d'Oncologie Médicale, Santé Individu Société (SIS), Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
[SHS.GEO] Humanities and Social Sciences/Geography ,[SHS.GEO]Humanities and Social Sciences/Geography ,[SHS] Humanities and Social Sciences ,ComputingMilieux_MISCELLANEOUS ,[SHS]Humanities and Social Sciences - Abstract
International audience
- Published
- 2016
14. Mise à jour 2023 des recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence des cancers gynécologiques
- Author
-
Joly, Florence and Ray-Coquard, Isabelle
- Published
- 2023
- Full Text
- View/download PDF
15. Répondre aux enjeux des cancers rares. Analyse géographique de la cohorte EMS des sarcomes en région Rhône-Alpes
- Author
-
Ducimetière, Françoise, Fayet, Yohan, Chasles, Virginie, Blay, Jean-Yves, Ray-Coquard, Isabelle, Chasles, Virginie, Santé Individu Société (SIS), Université Lumière - Lyon 2 (UL2)-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Santé Individu Société - SIS (SIS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Moulin - Lyon 3 (UJML), and Université de Lyon-Université Lumière - Lyon 2 (UL2)
- Subjects
[SHS.GEO] Humanities and Social Sciences/Geography ,[SHS.GEO]Humanities and Social Sciences/Geography ,[SHS] Humanities and Social Sciences ,ComputingMilieux_MISCELLANEOUS ,[SHS]Humanities and Social Sciences - Abstract
International audience
- Published
- 2014
16. Cluster analysis and principal component analysis to access the variability of data in cost evaluations: methods and applications in oncology
- Author
-
Perrier, Lionel, Buja, Alessandra, Mastrangelo, Giuseppe, Sylvestre-Baron, Patrick, Pauwels, Petrus, Rossi, Carlo, Gilly, François, Ducimetière, Françoise, Favier, Bertrand, Farsi, Fadila, Laramas, Mathieu, de Marliave, Hugues, Collard, Olivier, Cellier, Dominic, Blay, Jean-Yves, Ray-Coquard, Isabelle, Groupe d'analyse et de théorie économique (GATE Lyon Saint-Étienne), Centre National de la Recherche Scientifique (CNRS)-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université Lumière - Lyon 2 (UL2)-École normale supérieure - Lyon (ENS Lyon), Department of Environmental Medicine and Public Health, Universita degli Studi di Padova, Centre Léon Bérard [Lyon], Melanoma and Sarcomas Unit, Veneto Institute of Oncology, Service de Chirurgie Générale et Digestive, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon-Sud - RENAPE, Département d'Oncologie Médicale, Department of Pharmacy, Centre hospitalier universitaire de Grenoble (CHU de Grenoble), CHU Grenoble, Merck Serono, Merck & Co. Inc, Oncogénèse et progression tumorale, Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Médecine Nucléaire, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Groupe d'Analyse et de Théorie Economique Lyon - Saint-Etienne (GATE Lyon Saint-Étienne), École normale supérieure de Lyon (ENS de Lyon)-Université Lumière - Lyon 2 (UL2)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Centre National de la Recherche Scientifique (CNRS), and Università degli Studi di Padova = University of Padua (Unipd)
- Subjects
oncology ,cost-evaluation ,[SHS.ECO]Humanities and Social Sciences/Economics and Finance ,ComputingMilieux_MISCELLANEOUS - Abstract
International audience
- Published
- 2012
17. [PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]
- Author
-
Ray-Coquard, Isabelle, Chauvin, Franck, Leblanc, Eric, Caux, Christophe, Hoarau, Hélène, Bonnetain, Franck, Christophe, Véronique, Sastre-Garau, Xavier, Lazennec, Gwendal, Poulain, Laurent, Haie-Meder, Christine, Pujade-Lauraine, Eric, Salzet, Michel, Deutsch, Eric, Devouassoux, Mojgan, Penault Llorca, Frédérique, Lecuru, Fabrice, Taieb, Sophie, Arveux, Patrick, Theillet, Charles, Joly, Florence, Département d'Oncologie Médicale, Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Department of Surgery, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER-Université de Lille-UNICANCER, Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Département de Biologie des Tumeurs, Institut Curie [Paris], Cellules souches mésenchymateuses, environnement articulaire et immunothérapies de la polyarthrite rhumatoide, Université Montpellier 1 (UM1)-IFR3, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Régional d'Etudes sur le CANcer (GRECAN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-IFR146, Service d'Oncologie Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Neuroimmunologie des annélides (NA), Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Hopitaux de Paris, Université Paris Descartes - Paris 5 (UPD5), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Etienne, Université Lille Nord de France (COMUE)-UNICANCER-Université Lille Nord de France (COMUE)-UNICANCER, Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), IFR146-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU), Centre de Recherche en Cancérologie de Lyon (CRCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CRLCC Oscar Lambret, Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Institut Curie, IFR146-Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Université Paris Descartes - Paris 5 (UPD5)-Hôpital Hôtel-Dieu [Paris]-AP-HP, Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Centre Léon Bérard [Lyon]-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Santé-Individu-Société 'SIS', Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), INSTITUT CURIE, Université Montpellier 1 ( UM1 ) -IFR3-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Groupe Régional d'Etudes sur le CANcer ( GRECAN ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Centre Régional de Lutte contre le Cancer François Baclesse ( CRLC François Baclesse ) -IFR146, Université Paris Descartes - Paris 5 ( UPD5 ) -Hôpital Hôtel-Dieu [Paris]-AP-HP, Neuroimmunologie des annélides ( NA ), Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Institut de recherche en cancérologie de Montpellier ( IRCM - U896 Inserm - UM1 ), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier ( UM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Montpellier 1 ( UM1 ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Institut de recherche en cancérologie de Montpellier ( IRCM ), and Université Montpellier 1 ( UM1 ) -CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM )
- Subjects
Biomedical Research ,Uterine Cervical Neoplasms ,MESH : Early Detection of Cancer ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,MESH: Genital Neoplasms, Female ,Risk Factors ,MESH : Fertility ,MESH: Risk Factors ,MESH : Tumor Markers, Biological ,MESH : Female ,Immunologic Surveillance ,Early Detection of Cancer ,Ovarian Neoplasms ,DNA, Neoplasm ,MESH : Risk Factors ,MESH: Uterine Cervical Neoplasms ,MESH: Ovarian Neoplasms ,MESH: Sexuality ,MESH : Sexuality ,Female ,France ,MESH : DNA, Neoplasm ,MESH: Endometrial Neoplasms ,Sexuality ,MESH : Biomedical Research ,Genital Neoplasms, Female ,MESH : Uterine Cervical Neoplasms ,MESH : Genital Neoplasms, Female ,MESH: DNA, Neoplasm ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biomarkers, Tumor ,Humans ,MESH: Early Detection of Cancer ,MESH : France ,MESH: Immunologic Surveillance ,MESH: Humans ,MESH : Ovarian Neoplasms ,MESH: Biomedical Research ,MESH : Humans ,MESH: Quality of Life ,MESH: Fertility ,MESH : Quality of Life ,Endometrial Neoplasms ,MESH: France ,MicroRNAs ,MESH : MicroRNAs ,Fertility ,MESH : Endometrial Neoplasms ,MESH: Tumor Markers, Biological ,Quality of Life ,MESH : Immunologic Surveillance ,MESH: MicroRNAs ,MESH: Female - Abstract
International audience; Each year, 13,000 newly gynecologic cancers are diagnosed in France. Gynecologic cancers were specifically heterogeneous (localisations, histologic subgroups, age class, etc). This work was delineated for a national call dedicated to gynecologic cancers. This review reports the major needs in terms of scientific research dedicated to gynecologic cancers in the biologic, epidemiology, human and sociologic fields. For example, medico-economic strategies adapted to ethnosociologic context, specifically for cervix cancer, took important part of the epidemiologic research. Impact of gynecologic cancer in terms of symptoms and late effects, quality of life after treatments and fertility needs to be specifically explored. For fundamental research, molecular characterisation, biologic markers, impact of immunology and genetics represent the major part of the field need to be explored. Finally, therapeutic and diagnosis innovations, optimization of treatments strategies and development of predictive models in order to perform individual prediction taking into account several risk factors (clinical and molecular) to offer help in management of gynecologic cancers are required.
- Published
- 2012
18. Tumeurs malignes rares
- Author
-
RAY-COQUARD Isabelle, PEIX Jean-Louis, DROZ Jean-Pierre, RAY-COQUARD Isabelle, PEIX Jean-Louis, and DROZ Jean-Pierre
- Subjects
- Tumors, Cancer
- Abstract
Alors qu'il existe une littérature abondante fondée sur l'EBM (Evidence Based Medicine) concernant la prise en charge et le traitement des cancers les plus fréquents, celle-ci fait défaut pour les tumeurs malignes rares. L'ouvrage coordonné par les Professeurs Jean-Pierre Droz, Jean-Louis Peix et le Docteur Isabelle Ray-Coquard comble ce vide. Oncologues, spécialistes, chirurgiens cancérologues, anatomo-pathologistes, médecins généralistes, disposent à présent d'un ouvrage de référence en français sur ce thème. Il apporte une documentation essentielle sur les tumeurs rares ubiquitaires ou spécifiques de certains organes, sur les hémopathies rares, les tumeurs pédiatriques rares, mais aussi sur les syndromes paranéoplasiques, ou bien l'association cancer et grossesse. Par ailleurs, cet ouvrage aborde l'apport des techniques d'anatomie pathologique, de la génétique, de l'épidémiologie, de la médecine du travail pour la prise en charge de ces cancers. Il fournit des revues de la littérature récente, donne des pistes de recherches bibliographiques ainsi que des références de sites internet. Les illustrations permettent d'enrichir les connaissances cliniques, anatomo-pathologiques et radiologiques. Ce livre complète la littérature existante en recensant pour la première fois les données sur les cancers rares. Il deviendra l'outil indispensable en français pour tout spécialiste du cancer.
- Published
- 2010
19. [Prognostic factors for febrile neutropenia]
- Author
-
Ray-Coquard, Isabelle, Borg, Christophe, Bachelot, Thomas, Fayette, Jerome, Zufferey, Laura, Guastalla, Jean-Paul, Ghesquiere, Herve, Jean-Yves Blay, Sebban, Catherine, Marec-Berard, Perrine, Biron, Pierre, Centre Léon Bérard [Lyon], Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Saas, Philippe
- Subjects
MESH: Humans ,Neutropenia ,MESH: Neutropenia ,Fever ,MESH: Disease Susceptibility ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Antineoplastic Agents ,Antibiotic Prophylaxis ,Hematopoietic Cell Growth Factors ,Prognosis ,MESH: Hematinics ,MESH: Prognosis ,Recombinant Proteins ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,MESH: Antibiotic Prophylaxis ,MESH: Fever ,Granulocyte Colony-Stimulating Factor ,Hematinics ,MESH: Antineoplastic Agents ,Humans ,Disease Susceptibility ,MESH: Granulocyte Colony Stimulating Factor, Recombinant ,MESH: Hematopoietic Cell Growth Factors - Abstract
International audience; Cytotoxic chemotherapy suppresses the haematopoietic system, impairing host protective mechanisms and limiting the doses of chemotherapy that can be tolerated. Febrile neutropenia, the most serious haematological toxicity, is associated with the risk of life-threatening infections as well as chemotherapy dose reductions and delays that may compromise treatment outcomes. The recent literature in chemotherapy-induced neutropenia and its complications and impact was provided an update on research, and the implications for improving the management of patients with cancer who are treated with myelosuppressive chemotherapy was discussed. Despite its importance as the primary dose-limiting toxicity of chemotherapy, much concerning neutropenia and its consequences and impact remains unknown. Recent surveys indicate that neutropenia remains a prevalent problem associated with substantial morbidity, mortality, and costs. The colony-stimulating factors (CSFs) have been used effectively in a variety of clinical settings to prevent or treat febrile neutropenia and to assist patients receiving dose-intensive chemotherapy. A meta-analysis of the available randomized controlled trials (RCTs) has confirmed the efficacy of prophylactic CSFs. Much research has sought to identify risk factors that may predispose patients to neutropenic complications, including febrile neutropenia, in an effort to predict better which patients are at risk and to use preventive strategies, such as prophylactic colony-stimulating factors, more cost-effectively. Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs.
- Published
- 2004
20. Tumeurs rares malignes de l’ovaire.
- Author
-
Ray-Coquard, Isabelle, Guastalla, J.-P., Treilleux, I., Biron, P., Blay, J.-Y., Curé, H., Flechon, A., Lotz, J.-P., Méeus, P., Mignot, L., Raudrant, D., Tournigand, C., and Lauraine, E. Pujade
- Subjects
- *
OVARIAN tumors , *GERM cells , *LEYDIG cells , *SERTOLI cells , *THERAPEUTICS - Abstract
Germ cell tumours and ovarian sex cord tumours are extremely rare malignant diseases of the ovaries. Stromal tumours (Leydig cells) and/or sex cord tumours (Sertoli cells) represent approximately 5% of ovarian tumours and develop from the conjunctive tissue (interstitial and nurse cells respectively) of the ovaries. All together, they represented less than 20% of the malignant ovarian tumours in adults. Treatment of rare ovarian tumours is currently as follows: —surgery is the same as that for ovarian adenocarcinomas, with one major difference: conservation of the reproductive function in women of reproductive age is usual for this type of tumour; —chemotherapy, based on data reported in the literature, is the same as that prescribed for testicular germ-cell tumours; —surgery, chemotherapy and possible surgical intervention for residual lesions are highly complex. Also, these rare non epithelial malignant tumours are not very well understood as regards their prognostic factors. Too rare to be included in randomized studies, treatment of these tumours has benefited from the therapeutic advancements made against testicular germ-cell tumours and must be realized in specialized centres. Effectively, some factors such stage, histology and the number of managed patients seems to be prognostic for survival. Because of the rarity of these tumours, a specialized website (www.ovaire-rare.org) was developed in France in 2002. Objectives were to delineate prognostic factors of these very rare diseases; to favour patient inclusion in a clinical trial available online; to provide access to medical expert forums online (disease-related) for complex cases; and finally, to demonstrate the impact of these tools on improving medical practice. The website provides very interesting data for a better knowledge of these rare tumours and will possibly help improve medical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
21. Tumeur stromale colique asymptomatique révélée par un sarcome de Kaposi classique chez une malade VIH négative
- Author
-
Baty, Vincent, Blay, Jean-Yves, Michalet, Véronique, Prost, Bénédicte, Agard, Catherine, Ranchère-Vince, Dominique, Fontaumard, Eric, and Ray-Coquard, Isabelle
- Published
- 2004
- Full Text
- View/download PDF
22. Chapitre 11 - Traitements adjuvants du cancer du sein
- Author
-
Guastalla, Jean-Paul, Tredan, Olivier, Ray-Coquard, Isabelle, Labidi-Galy, Sana Intidhar, Duret, Aude, Cassier, Philippe, and Bachelot, Thomas
- Full Text
- View/download PDF
23. [Diagnosis of uterine sarcomas and rare uterine mesenchymal tumours with malignant potential. Guidelines of the French Sarcoma Group and Rare Gynaecological Tumours].
- Author
-
Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Le Frere Belda MA, Averous G, Leroux A, Bataillon G, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, and Genestie C
- Subjects
- Adult, Child, Female, Humans, Protein-Tyrosine Kinases, Proto-Oncogene Proteins, Receptor Protein-Tyrosine Kinases, DNA Helicases, Nuclear Proteins, Transcription Factors, Leiomyosarcoma diagnosis, Leiomyosarcoma genetics, Leiomyosarcoma therapy, Genital Neoplasms, Female, Rhabdomyosarcoma, Embryonal diagnosis, Rhabdomyosarcoma, Embryonal genetics, Rhabdomyosarcoma, Embryonal therapy, Sarcoma, Endometrial Stromal diagnosis, Sarcoma, Endometrial Stromal genetics, Sarcoma, Endometrial Stromal therapy, Uterine Cervical Neoplasms, Uterine Neoplasms diagnosis, Uterine Neoplasms genetics, Uterine Neoplasms therapy, Soft Tissue Neoplasms, Endometrial Neoplasms, Ribonuclease III, DEAD-box RNA Helicases
- Abstract
The landscape of uterine sarcomas is becoming more complex with the description of new entities associated with recurrent driver molecular alterations. Uterine sarcomas, in analogy with soft tissue sarcomas, are distinguished into complex genomic and simple genomic sarcomas. Leiomyosarcomas and undifferentiated uterine sarcomas belong to complex genomic sarcomas group. Low-grade and high-grade endometrial stromal sarcomas, other rare tumors associated with fusion transcripts (such as NTRK, PDGFB, ALK, RET ROS1) and SMARCA4-deficient uterine sarcoma are considered simple genomic sarcomas. The most common uterine sarcoma are first leiomyosarcoma and secondly endometrial stromal sarcomas. Three different histological subtypes of leiomyosarcoma (fusiform, myxoid, epithelioid) are identified, myxoid and epithelioid leiomyosarcoma being more aggressive than fusiform leiomyosarcoma. The distinction between low-grade and high-grade endometrial stromal sarcoma is primarily morphological and immunohistochemical and the detection of fusion transcripts can help the diagnosis. Uterine PEComa is a rare tumor, which is distinguished into borderline and malignant, according to a risk assessment algorithm. Embryonal rhabdomyosarcoma of the uterine cervix is more common in children but can also occur in adult women. Embryonal rhabdomyosarcoma of the uterine cervix is almost always DICER1 mutated, unlike that of the vagina which is wild-type DICER1, and adenosarcoma which can be DICER1 mutated but with less frequency. Among the emerging entities, sarcomas associated with fusion transcripts involving the NTRK, ALK, PDGFB genes benefit from targeted therapy. The integration of molecular data with histology and clinical data allows better identification of uterine sarcomas in order to better treat them., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. [Endometrial stromal sarcoma: French Guidelines from the French Sarcoma Group and the Rare Malignant Gynecologic Tumors Group].
- Author
-
Lebreton C, Meeus P, Genestie C, Croce S, Guyon F, Moscardo CL, Taieb S, Blay JY, Bonvalot S, Bompas E, Chevreau C, Lécuru F, Rossi L, Joly F, Rios M, Chaigneau L, Duffaud F, Pautier P, and Ray-Coquard I
- Subjects
- Female, Humans, Middle Aged, Sarcoma, Endometrial Stromal surgery, Sarcoma, Endometrial Stromal pathology, Endometrial Neoplasms surgery, Endometrial Neoplasms drug therapy, Genital Neoplasms, Female, Uterine Neoplasms surgery, Sarcoma therapy
- Abstract
Low-grade endometrial stromal sarcoma (LG-ESS) accounts for approximately 15% of all uterine sarcomas. Median age of patients is around 50 years and half of the patients are premenopausal. In all, 60% of cases present with FIGO stage I disease. Preoperatively radiologic findings of ESS are not specific. Pathological diagnosis remains essential. This review aimed to present the French guidelines for low grade ESS treatment within the Groupe sarcome français - Groupe d'étude des tumeurs osseuse (GSF-GETO)/NETSARC+ and tumeur maligne rare gynécologique (TMRG) networks. Treatments should be validated in multidisciplinary team involved in sarcomas or rare gynecologic tumors. Hysterectomy is the cornerstone of treatment for localized ESS, and morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome and is not recommended. Leaving the ovaries in situ in stage I tumors could be discussed for young women. Adjuvant hormonal treatment could be considered, for two years for stage I with morcellation or stage II and livelong for stages III or IV. Nevertheless, several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Tamoxifen is contraindicated. Secondary cytoreductive surgery if feasible for recurrent disease, appears to be an acceptable approach. Systemic treatment for recurrent or metastatic disease is mainly hormonal, with or without surgery., (Copyright © 2023. Published by Elsevier Masson SAS.)
- Published
- 2023
- Full Text
- View/download PDF
25. [Treatments for rare ovarian tumors: What's new?]
- Author
-
Lebreton C, Quesada S, Bini M, Babin G, Rossi L, Chopin N, Croce S, Hartog C, Renaud T, Gaillard AL, Petit A, Serre AA, Trédan O, Rowinski E, Cockenpot V, Treilleux I, Rousset-Jablonski C, Méeus P, Guyon F, and Ray-Coquard I
- Subjects
- Female, Humans, Precision Medicine, Incidence, Ovarian Neoplasms therapy, Ovarian Neoplasms pathology
- Abstract
Even if each rare ovarian tumor (ROT) has a low incidence, the sum of all these entities represents almost the half of all ovarian neoplasms. Thus, development of dedicated clinical trial emerged as a prerequisite to improve their managements. Owing to the spreading of dedicated institutional networks and (supra)national collaborations, the number of clinical trials has increased the past few years, with different types of trials; while some focused on specific molecular features, others assessed innovative molecules. Furthermore, relevant randomized clinical trials were designed as a mean to position new treatment options. Currently, innovative molecular-driven trials, based on master protocol trials are emerging and may shed light towards the improvement of personalized medicine regarding ROT., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
26. [Uterin sarcoma, high-grade stroma, indifferenciated, referential].
- Author
-
Roussel-Simonin C, Croce S, Guyon F, Llacer C, Ray-Coquard I, Meeus P, Genestie C, Taieb S, Malhaire C, Duffaud F, and Pautier P
- Subjects
- Female, Humans, Middle Aged, Combined Modality Therapy, Hysterectomy, Ovariectomy, Neoplasm Staging, Uterine Neoplasms surgery, Sarcoma surgery, Endometrial Neoplasms therapy, Endometrial Neoplasms pathology
- Abstract
High-grade endometrial stromal sarcoma (HGESS) and uterine undifferentiated sarcoma (UUS) are rare uterine malignancies arising from mesenchymal endometrial cells. They are characterized by aggressive behavior and poor prognosis. Median age of diagnostic is 55years. The most common symptoms are vaginal bleeding, abdominal pain, and pelvic mass. Approximately 65 % are diagnosed witch advance disease stage III or IV according to the International Federation of Gynecology and Obstetrics classification. Median overall survival is around 20months. The management of the disease must be discussed in multidisciplinary staff meetings. The standard management of HGESS and UUS is total hysterectomy with bilateral oophorectomy. Systematic lymphadenectomy is not recommended. Adjuvant therapies, such as chemotherapy and radiotherapy must be discussed. In case of oligo-metastasic disease, surgery of the primary tumor and metastasis must be discussed and if not operable the standard management is doxorubine-based chemotherapy., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
27. [Uterin adenosarcoma: French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group].
- Author
-
Karabajakian A, Genestie C, Meeus P, Guyon F, Llacer Moscardo C, Croce S, Taieb S, Duffaud F, Pautier P, Ray-Coquard I, and Blay JY
- Subjects
- Female, Humans, Neoplasm Recurrence, Local therapy, Hormones, Genital Neoplasms, Female therapy, Adenosarcoma surgery, Uterine Neoplasms surgery
- Abstract
Uterine adenosarcoma is a very rare malignancy defined as a biphasic tumor composed of both benign epithelial component and a malignant sarcoma component. The stage of the disease is determined by the presence of myometrial invasion and the extent of extra-uterine disease. The most important histopronostic factors are the existence of a sarcomatous overgrowth defined by a sarcomatous contingent occupying more than 25 % of the volume of the tumor (directly correlated to the grade of the disease), the presence of a heterologous and/or a high-grade component. Stage I adenosarcomas without sarcomatous overgrowth have a good prognosis, with an overall 5-year survival of up to 80 %. In localized disease, complete surgical removal is recommended. The role of hormone therapy, chemotherapy and adjuvant radiotherapy is not established. If possible, relapses should be re-treated surgically, with the aim of achieving complete resection. In the advanced inoperable or metastatic setting, hormone therapy is an option for low-grade adenosarcomas with estrogen receptor (ER) and progesterone receptor (PR) overexpression. For high-grade tumors, the standard chemotherapies are doxorubicin-based combinations, although an integrated approach of surgery and medical treatment should also be considered in this setting., (Copyright © 2023 Société Française du Cancer. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
28. [Homologous recombination deficiency in epithelial ovarian cancers: from molecular characterization to patient journey].
- Author
-
Quesada S, Solassol J, Ray-Coquard I, and Fabbro M
- Subjects
- Female, Humans, Carcinoma, Ovarian Epithelial genetics, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Poly(ADP-ribose) Polymerase Inhibitors pharmacology, Genomic Instability, Homologous Recombination, Ovarian Neoplasms pathology
- Abstract
High-grade serous ovarian carcinoma (HGSOC), the most frequent and aggressive form of epithelial ovarian cancer is characterized in half of cases by homologous recombination deficiency (HRD). This molecular alteration is defined by distinct causes and consequences. The main and most characterized cause is the presence of an alteration affecting BRCA1 and BRCA2 genes. Regarding consequences, a specific genomic instability leads to increased sensitivity to platinum salts and poly (ADP-ribose) polymerase (PARPi) inhibitors. This latter point enabled the advent of PARPi in first and second line maintenance. As such, the initial and rapid evaluation of HRD status with molecular tests is a key step in the management of HGSOC. Until recently, the range of tests offered proved to be very limited and suffered from technical and medical limitations. This has recently led to the development and validation of alternatives, including academic ones. This "state of the art" review will bring a synthesis concerning the assessment of HRD status in HGSOCs. After a brief introduction of HRD (including main causes and consequences) and of its predictive value regarding PARPi, we will discuss the limitations of current molecular tests and the existing alternatives. Finally, we will contextualize this to the situation in France, with special consideration concerning the positioning and the financial coverage of these tests, with the perspective of optimizing patient management ., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. [Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups].
- Author
-
Collineau B, Genestie C, Croce S, Meeus P, Floquet A, Guyon F, Llacer-Moscardo C, Lebreton C, Taieb S, Toulmonde M, Blay JY, Bonvalot S, Ray-Coquard I, Pautier P, and Duffaud F
- Subjects
- Female, Humans, Prognosis, Radiotherapy, Adjuvant, Hysterectomy methods, Leiomyosarcoma therapy, Leiomyosarcoma surgery, Uterine Neoplasms diagnosis, Uterine Neoplasms therapy, Sarcoma therapy, Soft Tissue Neoplasms
- Abstract
Uterine leiomyosarcomas represent the most common uterine sarcomas. The prognosis is poor with metastatic recurrence in more than half of the cases. The purpose of this review is to make French recommendations for the management of uterine leiomyosarcomas within the framework of the French Sarcoma Group - Bone Tumor Study Group (GSF-GETO)/NETSARC+ and Malignant Rare Gynecological Tumors (TMRG) networks in order to optimize their therapeutic management. The initial assessment includes a MRI with diffusion perfusion sequence. The diagnosis is histological with a review in an expert center (Reference Network in Sarcoma Pathology (RRePS)). Total hysterectomy with bilateral salpingectomy, en bloc without morcellation, is performed when complete resection is possible, whatever the stage. There is no indication of systematic lymph node dissection. Bilateral oophorectomy is indicated in peri-menopausal or menopausal women. Adjuvant external radiotherapy is not a standard. Adjuvant chemotherapy is not a standard. It can be an option and consists in doxorobucin based protocols. In the event of local recurrence, the therapeutic options are based on revision surgery and/or radiotherapy. Systemic treatment with chemotherapy is most often indicated. In case of metastatic disease, surgical treatment remains indicated when resecable. In cases of oligo-metastatic disease, focal treatment of metastases should be considered. In the case of stage IV, chemotherapy is indicated, and is based on first-line doxorubicin-based protocols. In the event of excessive deterioration in general condition, management by exclusive supportive care is recommended. External palliative radiotherapy can be proposed for symptomatic purposes., (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
30. [Current advances in immunotherapy in ovarian cancer].
- Author
-
Le Saux O, Dubois B, Stern MH, Terme M, Tartour E, Classe JM, Chopin N, Trédan O, Caux C, and Ray-Coquard I
- Subjects
- Antigens, Neoplasm, Antineoplastic Agents, Immunological therapeutic use, B7-H1 Antigen antagonists & inhibitors, CTLA-4 Antigen antagonists & inhibitors, Female, Humans, Immunotherapy trends, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive trends, Ovarian Neoplasms immunology, Immunotherapy methods, Ovarian Neoplasms drug therapy
- Abstract
Ovarian cancers express highly immunogenic tissue-specific antigens. The resulting immune infiltration is a major prognostic factor. There is therefore a strong biological rationale for the development of immunotherapy in ovarian cancer. However, based on Phase I and II clinical trials data, the efficacy of anti-PD-1 and anti-PD-L1 immune checkpoint inhibitors (ICPIs) remains limited in monotherapy in heavily pre-treated patients. Currently, the identification of predictive biomarkers of response and resistance is one of the major areas of research. Identifying effective combination of anti-PD-1 or anti-PD-L1 with other anticancer agents is another clinical need. Several combinations were evaluated. The association of ICPIs with chemotherapy (anthracyclines or carboplatin+paclitaxel) is disappointing (JAVELIN studies). The association with PARP inhibitors, anti-angiogenic agents and CTLA-4 inhibitors seems promising. Other immune therapies such as cell therapies (adoptive transfer of intra-tumor lymphocytes, CAR T cells or vaccines from dendritic cells) could be the future of immunotherapy in ovarian cancer but only early phase studies clinical data is available at this time., (Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
31. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
- Author
-
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, and Daraï E
- Subjects
- Antineoplastic Agents therapeutic use, Bevacizumab therapeutic use, Chemotherapy, Adjuvant, Female, France, Humans, Hyperthermia, Induced, Lymph Node Excision, Magnetic Resonance Imaging, Phthalazines therapeutic use, Piperazines therapeutic use, Societies, Medical, Ultrasonography, Carcinoma, Ovarian Epithelial diagnostic imaging, Carcinoma, Ovarian Epithelial drug therapy, Carcinoma, Ovarian Epithelial pathology, Carcinoma, Ovarian Epithelial surgery, Fallopian Tube Neoplasms diagnostic imaging, Fallopian Tube Neoplasms drug therapy, Fallopian Tube Neoplasms pathology, Fallopian Tube Neoplasms surgery, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Peritoneal Neoplasms diagnostic imaging, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms pathology, Peritoneal Neoplasms surgery
- Abstract
Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A)., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
32. [Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].
- Author
-
Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, and Joly Lobbedez F
- Subjects
- Adult, Age Factors, Aged, Cohort Studies, Disease Progression, Disease-Free Survival, Europe, Female, France, Health Surveys, Humans, Life Expectancy, Middle Aged, Neoplasm Recurrence, Local psychology, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy, Quality of Life, Tumor Burden, Health Knowledge, Attitudes, Practice, Maintenance Chemotherapy psychology, Ovarian Neoplasms drug therapy, Ovarian Neoplasms psychology, Patient Preference psychology
- Abstract
Background: Expression IV survey evaluated the patients' expectations to a maintenance therapy., Methods: From January 2015 to March 2016, 401 French patients, in first line or recurrent disease, answered a 24-items anonymous questionnaire. The results were specifically analyzed according to the demographic characteristics and treatment lines., Results: Among the patients, 62% had already been informed about maintenance therapy. Thirty-seven percent of patients received a maintenance treatment: 111 patients during first line and 39 patients in relapse. Expectations of patients were: 1) the chance of cure (73%), 2) the tumor shrinkage (36%), 3) quality of life improvement (35%) and 4) tumor growth reduction (27%). Among the responders, 42% were willing to take the treatment for 6-24 months, 20% for 24-60 months and 38% until tumor progression. 64% of patients expected more than a 6 months progression-free survival. Patients older than 70 years were less informed than their younger counterparts (48% vs 66%) and had lesser hope for cure with maintenance treatment (60% vs 77%). Patients in relapse had more expectation than patients in remission (tumor shrinkage: 47% vs 22%, slowing of tumor growth: 37% vs 15%, improving the progression-free survival of more than 6 months: 71% vs 53%, respectively). Among patients, 48% in relapse consented to take a treatment until progression vs 24% of patients in remission., Conclusion: This sub-analysis in French patients demonstrate a gap between the efficacy of maintenance therapy and the patients' expectations in ovarian cancer, particularly in relapsing disease justifying better information and explanations., (Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
33. [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer].
- Author
-
Rousset-Jablonski C, Selle F, Adda-Herzog E, Planchamp F, Selleret L, Pomel C, Chabbert-Buffet N, Daraï E, Pautier P, Trémollières F, Guyon F, Rouzier R, Laurence V, Chopin N, Faure-Conter C, Bentivegna E, Vacher-Lavenu MC, Lhomme C, Floquet A, Treilleux I, Lecuru F, Gouy S, Kalbacher E, Genestie C, de la Motte Rouge T, Ferron G, Devouassoux-Shisheboran M, Kurtz JE, Namer M, Joly F, Pujade-Lauraine E, Grynberg M, Querleu D, Morice P, Gompel A, and Ray-Coquard I
- Subjects
- Carcinoma, Ovarian Epithelial, Contraindications, Drug, Delphi Technique, Female, Humans, Neoplasms, Germ Cell and Embryonal pathology, Neoplasms, Germ Cell and Embryonal therapy, Neoplasms, Glandular and Epithelial pathology, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms pathology, Rare Diseases pathology, Contraception methods, Fertility Preservation methods, Infertility, Female therapy, Menopause, Premature, Ovarian Neoplasms therapy, Rare Diseases therapy
- Abstract
Introduction: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors., Methods: A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds., Results: Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors., Discussion: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients., (Copyright © 2017 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
34. Cancers de l’ovaire BRCA muté : consultation d’oncogénétique et prescription des inhibiteurs de PARP.
- Author
-
Gladieff L, Lyonnet DS, Lortholary A, Leary A, Genestie C, and Ray-Coquard I
- Subjects
- Antineoplastic Agents therapeutic use, Drug Resistance, Neoplasm, Fallopian Tube Neoplasms drug therapy, Fallopian Tube Neoplasms genetics, Female, Hematologic Diseases chemically induced, Humans, Maintenance Chemotherapy, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms genetics, Phthalazines therapeutic use, Piperazines therapeutic use, Poly(ADP-ribose) Polymerase Inhibitors therapeutic use, Adenocarcinoma drug therapy, Adenocarcinoma genetics, Genes, BRCA1, Genes, BRCA2, Mutation, Ovarian Neoplasms drug therapy, Ovarian Neoplasms genetics
- Abstract
Brca Mutated Ovarian Carcinomas: GENETIC COUNSELING AND PARP INHIBITORS PRESCRIPTION: Upon the availability of the PARP inhibitors in relapsed ovarian carcinoma, the pathways of the oncogenetic counseling were modified. Any research for a constitutional alteration of the BRCA1 and BRCA2 genes must be accompanied by an oncogenetic counseling. BRCA testing is recommended from the diagnosis to every woman with an ovarian or fallopian tube or peritoneum of high grade adenocarcinoma, whatever the age at the diagnosis and her family history. In case of sensitive relapse or potential inclusion in a clinical trial and in the absence of preliminary constitutional research, the oncogenetic counseling is organized according to a fast track pathway and a somatic analysis can be realized in parallel. Today, olaparib is indicated for patients with a high grade serous ovarian or fallopian tube or peritoneum adenocarcinoma, with deleterious mutation of BRCA genes (constitutional or somatic), and in sensitive platinum relapse, and in maintenance therapy after a response to chemotherapy including platinum. The indication of a treatment with olaparib can be discussed in multidisciplinary staff for the other non-serous high grade ovarian carcinoma if all other criteria are gathered. Olaparib is prescribed in monotherapy, to start at the latest 8 weeks after the last chemotherapy cycle, under narrow surveillance, because of its gastrointestinal and hematologic toxicities., (© 2017 Elsevier Masson SAS. Tous droits réservés.)
- Published
- 2017
- Full Text
- View/download PDF
35. [Innovative anticancer agents reserved to hospital use and not involved in the hospital budget: Creation and evolution].
- Author
-
Freyer G, Marty M, Blay JY, Chauffert B, Ganem G, Lotz JP, Marchal F, Medioni J, and Ray-Coquard I
- Subjects
- Economics, Hospital, Humans, Antineoplastic Agents therapeutic use, Budgets, Formularies, Hospital as Topic
- Published
- 2016
- Full Text
- View/download PDF
36. [Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?].
- Author
-
Devouassoux-Shisheboran M, Genestie C, and Ray-Coquard I
- Subjects
- Adenocarcinoma, Clear Cell pathology, Adenocarcinoma, Mucinous pathology, Brenner Tumor pathology, Carcinoma, Endometrioid pathology, Carcinoma, Ovarian Epithelial, Carcinosarcoma pathology, Cystadenocarcinoma, Serous pathology, Female, Humans, Mutation, Neoplasms, Glandular and Epithelial genetics, Ovarian Neoplasms genetics, Neoplasms, Glandular and Epithelial classification, Neoplasms, Glandular and Epithelial pathology, Ovarian Neoplasms classification, Ovarian Neoplasms pathology
- Abstract
Malignant epithelial tumors (carcinomas) are the most common ovarian cancers and the most lethal gynecological malignancies. Based on their heterogeneous morphology, a dualistic model of carcinogenesis was proposed in 2004. Type I carcinomas, composed of low grade serous, endometrioid, mucinous, clear cell carcinomas and malignant Brenner tumors, were distinct from type II carcinomas (high grade serous, undifferentiated carcinomas and carcinosarcomas). However, clinical studies failed to demonstrate the prognostic value of such a classification. The main reproach to this dualistic model was that it lumped together in type I tumors, heterogeneous lesions such as clear cell and mucinous carcinomas. Recent advances on molecular genetic alterations and precursor lesions favor the classification of ovarian carcinomas as five distinct diseases. The dualistic model of carcinogenesis in type I and II can finally be applied only to serous ovarian carcinomas (low grade and high grade)., (Copyright © 2016 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
37. [Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].
- Author
-
Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, and Gligorov J
- Subjects
- Adult, Aged, Analysis of Variance, Angiogenesis Inhibitors adverse effects, Bevacizumab adverse effects, Breast Neoplasms blood supply, Breast Neoplasms mortality, Creatinine blood, Female, France epidemiology, Humans, Hypertension mortality, Incidence, Kidney Function Tests, Middle Aged, Odds Ratio, Prevalence, Prognosis, Prospective Studies, Proteinuria mortality, Survival Analysis, Vascular Endothelial Growth Factors antagonists & inhibitors, Angiogenesis Inhibitors therapeutic use, Bevacizumab therapeutic use, Breast Neoplasms drug therapy, Hypertension epidemiology, Proteinuria epidemiology
- Abstract
Introduction: The potential prognostic value of hypertension and proteinuria of anti-vascular endothelial growth factor (VEGF) drugs has not been assessed in routine clinical practice so far in breast cancer. The objectives of the MARS study were to assess the prevalence of proteinuria and hypertension at baseline, their incidence under anti-VEGF treatment, and to evaluate a possible link with overall survival., Methods: Patients from 8 centres were included between 2009 and 2011 with a follow-up of 1 year. They were naive of any previous anti-VEGF treatment and planned to be started on one. The results of the group of patients with breast cancer receiving bevacizumab are presented., Results: Four hundred and two patients with breast cancer and treated with bevacizumab were included. At inclusion, hypertension prevalence was 12.4%, proteinuria 23.9%. The incidence of de novo proteinuria and hypertension during the follow-up was 61.7% and 16.8%, respectively. Among patients with de novo proteinuria, 62.2% afterwards improved/normalized. No thrombotic microangiopathy was reported. Baseline or de novo proteinuria/hypertension were not associated with overall survival in breast cancer patients treated with bevacizumab., Discussion: These results on the renovascular safety of bevacizumab in breast cancer patients showed that the prevalence of hypertension and proteinuria was high at baseline and, moreover, patients treated with bevacizumab frequently developed de novo hypertension and/or proteinuria. Finally, neither hypertension, nor proteinuria, neither at baseline, nor de novo, were associated with overall survival in our cohort of "real-life'' patients
- Published
- 2015
- Full Text
- View/download PDF
38. [Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?].
- Author
-
Heudel PE, Selle F, Morice P, Rouzier R, Taieb S, Devouassoux-Shisheboran M, Genestie C, Balleyguier C, and Ray-Coquard I
- Subjects
- Biopsy, Chemotherapy, Adjuvant methods, Contrast Media, Female, Humans, Laparoscopy, Laparotomy, Ovary pathology, Tomography, X-Ray Computed methods, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms pathology, Ovarian Neoplasms therapy
- Abstract
Because the majority of patients present advanced disease at diagnosis, the management of epithelial ovarian cancer needs specialist multidisciplinary teamwork. Expertise in surgery, chemotherapy, imaging and histopathology is essential to achieve optimum outcomes. Computed tomography scans are routinely used to determine the extent of disease and to aid in surgical planning. The histologic classification is crucial to plan the best therapeutic strategy and to define the prognosis of disease. Pathological prognostic factors, such as degree of differentiation, FIGO-stage, and histological type have to be described. This report is fundamental to assessing prognosis and selection of appropriate treatment strategy. An adequate staging procedure is an extensive staging by an experienced gynecological oncologist, exploring the entire upper abdomen, and the pelvic and para-aortic lymph node regions to define the Peritoneal Cancer Index (PCI). The final assessment is the completeness of cytoreduction (CC) score, which is an assessment of residual disease after a maximal surgical effort. Initial management of advanced ovarian cancer is best provided by a specialist multidisciplinary team, including a radiologist, a pathologist, a gynecologic oncologist and a medical oncologist., (Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
39. [Quinze questions importantes à se poser en oncologie en 2015].
- Author
-
Blay JY, Tredan O, Ray-Coquard I, Rivoire M, Mehlen P, Puisieux A, and Bachelot T
- Subjects
- Health Services Accessibility, Humans, Molecular Targeted Therapy trends, Neoplasms classification, Neoplasms genetics, Precision Medicine trends, Translational Research, Biomedical trends, Forecasting, Medical Oncology trends, Neoplasms therapy
- Abstract
Cancers can now be classified by multidimensional criteria including tumour site, histology, primary - "driver" - molecular alterations, secondary molecular alterations, characteristics of the immune stroma, and genetic profile of the patient. The development of tools for the characterisation of the cancers, as well as novel molecular and immune therapeutics are evolving at an unprecedented pace. In 2012, a list of future challenges was identified at the occasion of the European Organisation for Research and Treatment of Cancer (EORTC) 50(th) anniversary. Three years after, it is interesting to look back at the questions addressed then and to assess the progress of these questions. We propose here a novel set questions which have emerged from the recent publications in this area., (Copyright © 2015 Société Françise du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
40. [Molecular biology of sarcoma and therapeutic choices].
- Author
-
Dufresne A, Cassier P, Heudel P, Pissaloux D, Wang Q, Blay JY, and Ray-Coquard I
- Subjects
- Angiogenesis Inhibitors therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Benzamides therapeutic use, Bone Neoplasms genetics, Bone Neoplasms therapy, Crizotinib, Denosumab, Dermatofibrosarcoma genetics, Dermatofibrosarcoma therapy, Gastrointestinal Stromal Tumors genetics, Gastrointestinal Stromal Tumors therapy, Gene Amplification, Gene Deletion, Giant Cell Tumor of Bone genetics, Giant Cell Tumor of Bone therapy, Humans, Imatinib Mesylate, Indoles therapeutic use, Phenylurea Compounds therapeutic use, Piperazines therapeutic use, Point Mutation, Prognosis, Pyrazoles therapeutic use, Pyridines therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use, Sarcoma classification, Sarcoma, Ewing genetics, Sarcoma, Ewing therapy, Sunitinib, Synovitis, Pigmented Villonodular genetics, Synovitis, Pigmented Villonodular therapy, Translocation, Genetic, Molecular Targeted Therapy, Sarcoma genetics, Sarcoma therapy
- Abstract
Soft tissue sarcomas (STS) are a set of very heterogeneous tumors with numerous histological categories. The development of the molecular biology allowed identifying recurring molecular anomalies in certain subgroups of sarcomas, being able to represent diagnostic, prognosis and therapeutic tools. The molecular classification of STS includes until today 5 main groups of abnormalities: sarcomas with "simple genomic profile" showing reciprocal (1) chromosomal translocations, (2) activating mutation, (3) inhibitive mutation or (4) simple amplification; (5) sarcomas with "complex genomic profile" can include several tens of molecular abnormalities. The development of new-targeted therapies is based on the identification of a target, specific of a tumors subgroup and involved in carcinogenesis mechanisms and/or tumoral growth. Then, the aim of clinical research is to establish the proof of the concept through clinical trials, demonstrating the benefit brought to the patient and ending in the marketing of the drug. This proof of the concept was clearly established for imatinib, sunitinib and regorafenib in gastrointestinal stromal tumors, for imatinib in dermatofibrosarcoma protuberans and pigmented vilo-nodular synovitis, for denosumab in giant cell tumors of the bone, ending in the authorization to use these new therapies in these indications. It is in progress and promising for anti-IGF-1R in Ewing sarcomas, for crizotinib in myofibroblastic inflammatory tumors, for mTOR inhibitor in PEComas... The role of molecular abnormalities identified in the mechanisms of tumoral progress for sarcomas and their potential therapeutic impact will be detailed., (Copyright © 2015. Published by Elsevier Masson SAS.)
- Published
- 2015
- Full Text
- View/download PDF
41. [To answer rare cancer issues. Geographical analysis of EMS sarcoma cohort in the Rhône-Alpes region].
- Author
-
Fayet Y, Chasles V, Ducimetière F, Collard O, Berger C, Meeus P, Ranchère-Vince D, Thiesse P, Sunyach MP, Marec-Bérard P, Poncet L, Cousin P, Blay JY, and Ray-Coquard I
- Subjects
- Adult, Aged, France epidemiology, Gastrointestinal Stromal Tumors pathology, Humans, Liposarcoma pathology, Middle Aged, Rare Diseases pathology, Gastrointestinal Stromal Tumors epidemiology, Geography, Medical, Liposarcoma epidemiology, Rare Diseases epidemiology
- Abstract
Rare cancer issues have not been much explored yet because of their low incidence. That is why epidemiological studies have difficulties in identifying indisputable etiological risk factors. An expert opinion, mainly concentrated in some establishments, is required for these cancers' management. However, on account of the potential remoteness of these therapeutic resources, the patients' way of care remains also unstudied. By means of a geographical analysis of a regional exhaustive cohort of sarcoma, diagnosed in 2006 and 2007 and followed during five years at least, we can make progress on these different issues. Gastro-Intestinal and Stromal Tumors (GIST) occur more frequently in privileged territories while liposarcomas arise in more deprived areas. The association between liposarcomas and areas deprivation is significant (P=0.05). Moreover, pre-operative biopsy and some clinical patient characteristics, age, grade or tumor localization, are associated with an increase in the distance covered by patients for the first-line treatment (p ≤ 0,001). In the scope of an interdisciplinary collaboration, the geographical approach develops some hypothesis for rare cancers research, which must be tested by other larger scale studies.
- Published
- 2014
- Full Text
- View/download PDF
42. [Care networks in oncology, an evidence for all?].
- Author
-
Ray-Coquard I, Ducimetière F, and Farsi F
- Subjects
- Cancer Care Facilities organization & administration, Delivery of Health Care standards, Evidence-Based Practice, France, Humans, Medical Oncology standards, Neoplasms pathology, Pathology, Clinical organization & administration, Rare Diseases pathology, Regional Medical Programs standards, Delivery of Health Care organization & administration, Medical Oncology organization & administration, Neoplasms therapy, Rare Diseases therapy, Regional Medical Programs organization & administration
- Published
- 2013
43. [Iron deficiency and anemia in oncology].
- Author
-
Scotté F, Launay-Vacher V, and Ray-Coquard I
- Subjects
- Anemia blood, Anemia therapy, Antineoplastic Agents adverse effects, Erythropoiesis physiology, Erythropoietin deficiency, Fatigue etiology, Humans, Iron therapeutic use, Iron, Dietary administration & dosage, Kidney Failure, Chronic complications, Neoplasms blood, Neoplasms drug therapy, Practice Guidelines as Topic, Anemia chemically induced, Erythropoietin therapeutic use, Hematinics therapeutic use, Iron Deficiencies, Neoplasms complications
- Abstract
Anemia in oncology is no longer seen only as a side effect of chemotherapies. This comorbidity may be multifactorial, clinically and, for example, may be rather chronic when the patient has chronic renal failure associated, resulting in renal anemia. Similarly, the presence of iron deficiency, which can be solely responsible or contributing factor of anemia, is also a factor to be taken into account in both the diagnosis and exploration of anemia and in its treatment, requiring the use of injectable iron complexes for treatment, if necessary in combination with an erythropoiesis agent stimulating.
- Published
- 2012
- Full Text
- View/download PDF
44. [PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].
- Author
-
Ray-Coquard I, Chauvin F, Leblanc E, Caux C, Hoarau H, Bonnetain F, Christophe V, Sastre-Garau X, Lazennec G, Poulain L, Haie-Meder C, Pujade-Lauraine E, Salzet M, Deutsch E, Devouassoux M, Penault Llorca F, Lecuru F, Taieb S, Arveux P, Theillet C, and Joly F
- Subjects
- Biomarkers, Tumor blood, Biomedical Research, DNA, Neoplasm blood, Early Detection of Cancer, Endometrial Neoplasms pathology, Female, Fertility, France epidemiology, Humans, Immunologic Surveillance immunology, MicroRNAs analysis, Ovarian Neoplasms epidemiology, Ovarian Neoplasms genetics, Ovarian Neoplasms immunology, Ovarian Neoplasms pathology, Ovarian Neoplasms psychology, Ovarian Neoplasms therapy, Quality of Life, Risk Factors, Sexuality, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms immunology, Uterine Cervical Neoplasms psychology, Uterine Cervical Neoplasms therapy, Genital Neoplasms, Female diagnosis, Genital Neoplasms, Female epidemiology, Genital Neoplasms, Female genetics, Genital Neoplasms, Female immunology, Genital Neoplasms, Female psychology, Genital Neoplasms, Female therapy
- Abstract
Each year, 13,000 newly gynecologic cancers are diagnosed in France. Gynecologic cancers were specifically heterogeneous (localisations, histologic subgroups, age class, etc). This work was delineated for a national call dedicated to gynecologic cancers. This review reports the major needs in terms of scientific research dedicated to gynecologic cancers in the biologic, epidemiology, human and sociologic fields. For example, medico-economic strategies adapted to ethnosociologic context, specifically for cervix cancer, took important part of the epidemiologic research. Impact of gynecologic cancer in terms of symptoms and late effects, quality of life after treatments and fertility needs to be specifically explored. For fundamental research, molecular characterisation, biologic markers, impact of immunology and genetics represent the major part of the field need to be explored. Finally, therapeutic and diagnosis innovations, optimization of treatments strategies and development of predictive models in order to perform individual prediction taking into account several risk factors (clinical and molecular) to offer help in management of gynecologic cancers are required.
- Published
- 2012
- Full Text
- View/download PDF
45. [Anticancer drugs management in renal insufficiency patients].
- Author
-
Zimmer-Rapuch S, Lheureux S, Brocard F, Janus N, Launay-Vacher V, and Ray-Coquard I
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Dose-Response Relationship, Drug, Fluid Therapy, Glomerular Filtration Rate, Humans, Neoplasms drug therapy, Renal Insufficiency therapy, Risk Factors, Antineoplastic Agents pharmacokinetics, Kidney drug effects, Renal Insufficiency metabolism
- Abstract
Anticancer drug management is complicated especially in renal insufficiency patients, a frequent situation in oncology. Several aspects need to be taken into account: first, the dosage. In this population, the kidney fails to eliminate drugs. Consequently, dosage adjustment can be necessary for drugs with pharmacokinetic profile altered by renal insufficiency in order to avoid dose-related side effects due to accumulation of the drug. Secondly, renal tolerance is an important aspect of anticancer drug management as renal insufficiency is a risk factor for developing renal side effects. Prevention of renal side effects is essential and means to limit this toxicity should be used, especially with hydration. Finally, it is essential to consider all the treatments prescribed in renal insufficiency patients in order to avoid accumulation of nephrotoxic drugs.
- Published
- 2012
- Full Text
- View/download PDF
46. [Renal insufficiency and breast cancer].
- Author
-
Beuzeboc P, Le Tourneau C, Gligorov J, Janus N, Spano JP, Ray-Coquard I, Deray G, and Launay-Vacher V
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents administration & dosage, Bevacizumab, Bone Neoplasms drug therapy, Bone Neoplasms secondary, Breast Neoplasms complications, Breast Neoplasms metabolism, Creatinine metabolism, Dehydration complications, Diphosphonates adverse effects, Female, Glomerular Filtration Rate, Humans, Imidazoles adverse effects, Middle Aged, Renal Insufficiency metabolism, Young Adult, Zoledronic Acid, Antineoplastic Agents adverse effects, Breast Neoplasms drug therapy, Kidney drug effects, Renal Insufficiency complications
- Abstract
The Renal Insufficiency and Anticancer Medications (IRMA) study is a French national, observational study, which demonstrated the high prevalence of abnormal renal function in a population of 4,684 solid tumour patients, treated in 15 cancer centers. Among them, 7.2% had a SCR level ≥ 110 mmol/L. In the 1,898 patients with breast cancer, only 31 patients (1.63%) had a SCR level ≥ 110 mmol/L. Nevertheless, respectively 51.8 and 50.8% had a creatinine clearance estimated with the Cockcroft-Gault and aMDRD formulae, below 90 mL/min. Even if the most used medications (anthracyclins, taxanes, trastuzumab, hormone therapies) are not nephrotoxic, these results are important because bevacizumab modifies the need for renal management. In case of renal insufficiency, some other treatments such biphosphonates IV, capecitabin and platin salts need drug dosage adjustment or interruption.
- Published
- 2012
- Full Text
- View/download PDF
47. [Cervix cancer and corpus cancer of the uterus].
- Author
-
Tredan O, Ray-Coquard I, Arnaud A, Racadot S, and Guastalla JP
- Subjects
- Female, Humans, Uterine Neoplasms diagnosis, Uterine Neoplasms therapy, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms therapy
- Published
- 2011
48. [Antihormonal therapy in breast cancer and mTOR inhibitors].
- Author
-
Heudel PÉ, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, and Bachelot T
- Subjects
- Breast Neoplasms metabolism, Drug Resistance, Neoplasm, Everolimus, Female, Humans, Neoplasm Proteins metabolism, Phosphatidylinositol 3-Kinases metabolism, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins c-akt metabolism, Sirolimus therapeutic use, TOR Serine-Threonine Kinases metabolism, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Neoplasm Proteins antagonists & inhibitors, Neoplasms, Hormone-Dependent drug therapy, Sirolimus analogs & derivatives, TOR Serine-Threonine Kinases antagonists & inhibitors
- Abstract
Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy. Now, we know that this resistance may be related to a dysfunction of the estrogen pathway, or that of growth factors and particularly the pathway of cell activation PI3K/Akt/mTOR. Prevention of these different mechanisms of resistance could involve combination therapies such as anti-estrogens (SERMs, aromatase inhibitors) with inhibitors of the activity of growth factors that are particularly temsirolimus and everolimus for the activation pathway cell PI3K/Akt/mTOR.
- Published
- 2011
- Full Text
- View/download PDF
49. [Targeted therapy of sarcomas].
- Author
-
Cassier PA, Dufresne A, El Sayadi H, Pissaloux D, Alberti L, Decouvelaere AV, Ranchere D, Ray-Coquard I, and Blay JY
- Subjects
- Angiogenesis Inhibitors therapeutic use, Antineoplastic Agents therapeutic use, Gastrointestinal Stromal Tumors genetics, Humans, Protein Kinase Inhibitors therapeutic use, Sarcoma classification, Sarcoma genetics, Gastrointestinal Stromal Tumors drug therapy, Sarcoma drug therapy
- Abstract
Recent progress made in the field of sarcoma biology has shed new light on the pathophysiology of these numerous but rare diseases. Soft tissue sarcomas can be divided into 6 sub-types based on the underlying molecular biology of the disease: 1) translocation leading to fusion proteins involving transcription factors or growth factors (Ewing sarcoma, myxoid liposarcoma, dermatofibrosarcoma protuberans); 2) tyrosine kinase receptor mutations (gastrointestinal stromal tumors); 3) tumor-suppressor gene deletion (type 1 neurofibromatosis, rhabdoid tumors); 4) genetic alteration such as amplification of chromosomal regions (well differentiated/dedifferentiated liposarcoma); 5) sarcomas with more complex genetic alterations (leiomyosarcoma) and 6) abnormalities involving the cell-adhesion pathways (aggressive fibromatosis). Together with the current development of numerous targeted therapies, these recent progress are the basis of tomorrow's personalised medicine for patients with soft tissue sarcoma.
- Published
- 2008
- Full Text
- View/download PDF
50. [Adjuvant therapies: the example of breast cancer].
- Author
-
Bachelot T, Guastalla JP, and Ray-Coquard I
- Subjects
- Combined Modality Therapy, Female, Humans, Meta-Analysis as Topic, Breast Neoplasms therapy
- Abstract
Adjuvant chemotherapy, initiated following surgery, aims at controlling "microscopic" metastatic disease before its progression to a "clinical" recurrence. Its efficiency in localized breast cancer was officially demonstrated in 1992 in the Early Breast Cancer Trialists' Collaborative Group meta-analysis. This analysis helped clarify the benefits of therapeutic interventions according to progression stage, age and tumour biological features, especially in the presence of hormone receptors. Later on, new trials further defined the benefits of modern therapies, and especially trastuzumab in patients overexpressing HER2. The assessment of the theoretical benefits of adjuvant therapies takes into account the risk of individual recurrence and the potential decrease of the latter following a given therapeutic intervention--this decrease depending on tumor biological features. Deciding whether an adjuvant therapy should be initiated is difficult since benefits (observed in the long term) are often moderate while toxicities (immediately observed) are significant. The development of national and regional therapeutic guidelines markedly diminished the arbitrary aspect of the decision. Developing tools which could help implying the patient in this therapeutic decision is a priority.
- Published
- 2008
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.